Skip to content
TrialScanner

NCT02314247

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Phase 2TerminatedKPTIQLead

Registry record

Lead sponsor
Karyopharm Therapeutics Inc
Conditions
Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL)
Primary completion
Jan 2016Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02314247 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.